sb 202190 has been researched along with Chronic Disease in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In four of ten rats, seizure frequency was unaltered by LEV (non-responders)." | 1.42 | Blockade of endothelin B receptor improves the efficacy of levetiracetam in chronic epileptic rats. ( Kang, TC; Ko, AR, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ko, AR | 1 |
| Kang, TC | 1 |
1 other study available for sb 202190 and Chronic Disease
| Article | Year |
|---|---|
Blockade of endothelin B receptor improves the efficacy of levetiracetam in chronic epileptic rats.
Topics: Animals; Anticonvulsants; Brain; Chronic Disease; Disease Models, Animal; Endothelin B Receptor Anta | 2015 |